Bhaskar Rege

427 total citations
31 papers, 325 citations indexed

About

Bhaskar Rege is a scholar working on Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience. According to data from OpenAlex, Bhaskar Rege has authored 31 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Psychiatry and Mental health, 6 papers in Pharmacology and 6 papers in Cognitive Neuroscience. Recurrent topics in Bhaskar Rege's work include Pharmacogenetics and Drug Metabolism (6 papers), Sleep and Wakefulness Research (5 papers) and Pharmaceutical studies and practices (5 papers). Bhaskar Rege is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Sleep and Wakefulness Research (5 papers) and Pharmaceutical studies and practices (5 papers). Bhaskar Rege collaborates with scholars based in United States, United Kingdom and Japan. Bhaskar Rege's co-authors include Jim Ferry, Mohamadi Sarkar, Jagadeesh Aluri, Richard J. Krieg, Edgar Schuck, Börje Darpö, David Han, Yihan Lu, Joseph K. Ritter and Guillermo Rossiter and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Neurology.

In The Last Decade

Bhaskar Rege

30 papers receiving 310 citations

Peers

Bhaskar Rege
Christiane Tillmann Germany
Stefan Freudenthaler Germany
AF Cohen Netherlands
Chang Qiu China
Tamara Božina Croatia
Onno L. de Klerk Netherlands
Bob G. Schultz United States
Carmen Belmonte Spain
Dirk Thomas Germany
Yin Hu China
Christiane Tillmann Germany
Bhaskar Rege
Citations per year, relative to Bhaskar Rege Bhaskar Rege (= 1×) peers Christiane Tillmann

Countries citing papers authored by Bhaskar Rege

Since Specialization
Citations

This map shows the geographic impact of Bhaskar Rege's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bhaskar Rege with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bhaskar Rege more than expected).

Fields of papers citing papers by Bhaskar Rege

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bhaskar Rege. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bhaskar Rege. The network helps show where Bhaskar Rege may publish in the future.

Co-authorship network of co-authors of Bhaskar Rege

This figure shows the co-authorship network connecting the top 25 collaborators of Bhaskar Rege. A scholar is included among the top collaborators of Bhaskar Rege based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bhaskar Rege. Bhaskar Rege is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Citrome, Leslie, Christoph U. Correll, Andrew J. Cutler, et al.. (2025). Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia. Neuropsychiatric Disease and Treatment. Volume 21. 575–596. 2 indexed citations
2.
Grunstein, Ronald R., et al.. (2025). The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: An Initial Proof of Concept Phase 1b Study (P8-4.004). Neurology. 104(7_Supplement_1). 1 indexed citations
3.
Grunstein, Ronald R., Brendon J. Yee, Julia L. Chapman, et al.. (2025). 0838 The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy or Idiopathic Hypersomnia: A Phase 1b Study. SLEEP. 48(Supplement_1). A363–A364.
4.
Modi, Meera E., Brendon J. Yee, Julia L. Chapman, et al.. (2025). 0830 Effects of the Orexin 2 Receptor Agonist ALKS 2680 on qEEG in Patients with Narcolepsy and Idiopathic Hypersomnia. SLEEP. 48(Supplement_1). A360–A360. 1 indexed citations
5.
Yee, Brendon J., Julia L. Chapman, Ronald R. Grunstein, et al.. (2023). O013 Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin-2 receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia. SLEEP Advances. 4(Supplement_1). A5–A6. 3 indexed citations
6.
Piha‐Paul, Sarina A., Justin Call, Alexander I. Spira, et al.. (2023). 744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3). SHILAP Revista de lepidopterología. A839–A840. 1 indexed citations
7.
Sun, Lei, Richard J. Mills, Brian M. Sadler, & Bhaskar Rege. (2021). Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia. The Journal of Clinical Pharmacology. 61(11). 1430–1441. 11 indexed citations
8.
Sommi, Roger W., et al.. (2020). Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. CNS Spectrums. 27(3). 262–267. 6 indexed citations
9.
Sun, Lei, Narinder Nangia, David McDonnell, et al.. (2020). Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 100. 109881–109881. 14 indexed citations
10.
Jain, Rakesh K., Jonathan M. Meyer, Angela Wehr, et al.. (2019). Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS Spectrums. 25(3). 323–330. 20 indexed citations
11.
Renfroe, J. Ben, Mark Mintz, Ronald L. Davis, et al.. (2019). Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to <12 Years of Age With Epilepsy: Pharmacokinetics, Safety, Tolerability, and Efficacy. Journal of Child Neurology. 34(5). 284–294. 31 indexed citations
12.
Schuck, Edgar, Bhaskar Rege, Antonio Laurenza, et al.. (2017). Predictions of the pharmacokinetic profile of perampanel during pregnancy using physiologically based pharmacokinetic (PBPK) modeling (P3.237). Neurology. 88(16_supplement). 1 indexed citations
13.
Christopher, Ronald, Jim Ferry, Bhaskar Rege, et al.. (2016). Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet. Clinical Therapeutics. 38(10). 2227–2238.e4. 10 indexed citations
14.
15.
Schuck, Edgar, et al.. (2010). P3‐415: E2012, a novel gamma‐secretase modulator, decreases plasma amyloid‐beta (Aβ) levels in humans. Alzheimer s & Dementia. 6(4S_Part_19). 20 indexed citations
16.
Yu, Chuanhui, et al.. (2006). EFFECT OF CHRONIC RENAL INSUFFICIENCY ON HEPATIC AND RENAL UDP-GLUCURONYLTRANSFERASES IN RATS. Drug Metabolism and Disposition. 34(4). 621–627. 29 indexed citations
17.
Rege, Bhaskar, Richard J. Krieg, Ning Gao, & Mohamadi Sarkar. (2003). Down-Regulation of Hepatic CYP3A in Chronic Renal Insufficiency. Pharmaceutical Research. 20(10). 1600–1606. 15 indexed citations
18.
Rege, Bhaskar, et al.. (2002). Irreversible Inhibition of CYP2D6 by (−)-Chloroephedrine, a Possible Impurity in Methamphetamine. Drug Metabolism and Disposition. 30(12). 1337–1343. 7 indexed citations
19.
Rege, Bhaskar, Clark March, & Mohamadi Sarkar. (2002). Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes. Biomedical Chromatography. 16(1). 31–31. 1 indexed citations
20.
Rege, Bhaskar, Clark March, & Mohamadi Sarkar. (2001). Development of a rapid and sensitive high‐performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes. Biomedical Chromatography. 16(1). 31–40. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christiane Tillmann Breakdown of academic impact, for papers by Stefan Freudenthaler Breakdown of academic impact, for papers by AF Cohen Breakdown of academic impact, for papers by Chang Qiu Breakdown of academic impact, for papers by Tamara Božina Breakdown of academic impact, for papers by Onno L. de Klerk Breakdown of academic impact, for papers by Bob G. Schultz Breakdown of academic impact, for papers by Carmen Belmonte Breakdown of academic impact, for papers by Dirk Thomas Breakdown of academic impact, for papers by Yin Hu
Rankless by CCL
2026